MIRA INFORM REPORT

 

 

Report Date :

08.09.2012

 

IDENTIFICATION DETAILS

 

Name :

CASDA BIOMATERIALS CO., LTD.

 

 

Registered Office :

No. 86, Dongfeng Road, North Industrial Park, Taocheng District, Hengshui, Hebei Province, 053000 Pr

 

 

Country :

China

 

 

Date of Incorporation :

25.01.2010

 

 

Com. Reg. No.:

131100400002528

 

 

Legal Form :

Wholly Foreign-Owned Enterprise

 

 

Line of Business :

manufacturing and selling decanedioic acid and other chemicals

 

 

No. of Employees :

600

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

No Complaints

Litigation :

Clear

 


 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

China

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

CHINA - ECONOMIC OVERVIEW

 

Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, creation of a diversified banking system, development of stock markets, rapid growth of the private sector, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors it considers important to "economic security," explicitly looking to foster globally competitive national champions. After keeping its currency tightly linked to the US dollar for years, in July 2005 China revalued its currency by 2.1% against the US dollar and moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2010 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic demand; (b) sustaining adequate job growth for tens of millions of migrants and new entrants to the work force; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. In 2010-11, China faced high inflation resulting largely from its credit-fueled stimulus program. Some tightening measures appear to have controlled inflation, but GDP growth consequently slowed to near 9% for 2011. An economic slowdown in Europe is expected to further drag Chinese growth in 2012. Debt overhang from the stimulus program, particularly among local governments, and a property price bubble challenge policy makers currently. The government's 12th Five-Year Plan, adopted in March 2011, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent on exports in the future. However, China has made only marginal progress toward these rebalancing goals.

 

 

Source : CIA

 


Company name & address 

 

CASDA BIOMATERIALS Co., Ltd.

NO. 86, DONGFENG ROAD, NORTH INDUSTRIAL PARK, TAOCHENG DISTRICT, HENGSHUI, HEBEI PROVINCE, 053000 PR CHINA

TEL: 86 (0) 318-2124248 / 2229615         FAX: 86 (0) 318-2101356

 

 

EXECUTIVE SUMMARY

 

INCORPORATION DATE            : Jan. 25, 2010

REGISTRATION NO.                  : 131100400002528

REGISTERED LEGAL FORM     : Wholly foreign-owned enterprise

CHIEF EXECUTIVE                       : MR. DOMINIQUE GERARD NAMER (CHAIRMAN)

STAFF STRENGTH                    : 600

REGISTERED CAPITAL             : CNY 419,180,000

BUSINESS LINE                        : MANUFACTURING and trading

TURNOVER                              : N/A

EQUITIES                                 : N/A

PAYMENT                                : AVERAGE

MARKET CONDITION                : AVERAGE

FINANCIAL CONDITION             : N/A

OPERATIONAL TREND              : FAIRLY STEADY

GENERAL REPUTATION           : AVERAGE

EXCHANGE RATE                     : CNY 6.3468 = USD 1

 

Adopted abbreviations:

ANS - amount not stated           

NS - not stated 

SC - subject company (the company inquired by you)

NA - not available          

CNY - China Yuan Renminbi

 


 

Rounded Rectangle: HISTORY 

 

 


SC was registered as a Chinese-foreign equity joint venture enterprise at local Administration for industry & commerce (AIC - the official body of issuing and renewing business license) on Jan. 25, 2010, and later was changed into present legal form.

 

Company Status: Wholly foreign-owned enterprise

This form of business in PR China is defined as a legal person. It is a limited co. established within the territories of PR China with capital provided totally by the foreign investors. More than one foreign investor may jointly invest in a wholly foreign-owned enterprise. The investing party/parties solely exercise management, reap profit and bear risks and liabilities by themselves. This form of companies usually have a limited duration is extendible upon approval of Examination and Approval Authorities.

 

 

 

 

 

 

 

 

 

 

 

 

SC’s registered business scope includes manufacturing decanedioic acid, sebacate of dimethyl sebacate, 2-Octanol, glycerol, aliphatic acid; selling its products.

 

SC is mainly engaged in manufacturing and selling decanedioic acid and other chemicals.

 

Mr. Dominique Gerard Namer is legal representative and chairman of SC at present.

 

SC is known to have approx. 600 employees at present.

 

SC is currently operating at the above stated address, and this address houses its operating office and factory in the industrial zone of Hengshui. The detailed information of the premise is unspecified.

 

Rounded Rectangle: WEB SITE 

 


http://www.casdabm.com The design is professional and the content is well organized. At present it is in Chinese version.

 

SC has another website: http://www.sebacic-acid.com The design is professional and the content is well organized. At present it is both in Chinese and English versions.

 

Email: xz.wang@casdabm.com ; sales@sebacic-acid.com

 

 

Rounded Rectangle: KEY EVENTS/RECENT DEVELOPMENT 

 

 


Changes of its registered information are as follows:

Date of change

Item

Before the change

After the change

2010-6-30

Registered capital

CNY 394,870,000

The present amount

Shareholders and shareholding

Hengshui Dongfeng Chemical Co., Ltd. 30%

Warsin International Limited (Hong Kong)  70%

Hengshui Dongfeng Chemical Co., Ltd. 34.59%

Warsin International Limited (Hong Kong) 65.41%

Unknown

Shareholders and shareholding

Hengshui Dongfeng Chemical Co., Ltd. 34.59%

Warsin International Limited (Hong Kong) 65.41%

Present one

Legal rep.

Li Ji

Present one

Legal form

Chinese-foreign equity joint venture enterprise

Present one

 

 

Rounded Rectangle: OWNERSHIP/MANAGEMENT BACKGROUND 

 

 


MAIN SHAREHOLDERS:

 

Name                                                                                                  % of Shareholding

Arkema Asie Sas (France)                                                                                  100

 

 

Rounded Rectangle: MANAGEMENT 

 

 


Legal Representative and Chairman:

Mr. Dominique Gerard Namer, French. He is currently responsible for the overall management of SC.

 

Working Experience(s):

At present                     Working in SC as legal representative and chairman.

 

Directors:

Zhang Liqun

Shi Baochang

Lionel Marcel Raymond Guerdoux

 

Supervisor:

Benjamin, Olivier, Pierre, Ghislain Jacquot

 

 

Rounded Rectangle: BUSINESS OPERATIONS
 BACKGROUND
 

 

 


SC is mainly engaged in manufacturing and selling decanedioic acid and other chemicals.

 

SC’s products mainly include decanedioic acid, sebacic acid, dimethyl sebacate, etc.

 

SC sources its materials 40% from domestic market, and 60% from overseas market, mainly India. SC sells 30% of its products in domestic market, and 70% to overseas mark, mainly Europe.

 

The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days. The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.

 

Note: SC’s management declined to release its customer and supplier details.

 

 

Rounded Rectangle: RELATED COMPANIES

 BACKGROUND
 

 

 


According to the website: http://www.arkema.co.jp

Arkema K.K.

Head Office: Fukoku-Seimei Bldg., 15F, 2-2-2, Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011

TEL +81-3-5251-9900/5251-9493/5251-9917

FAX +81-3-5251-9930

 

Rounded Rectangle: PAYMENT

 BACKGROUND
 

 

 


Overall payment appraisal:

(  ) Excellent      (  ) Good      (X) Average      (  ) Fair      (  ) Poor      (  ) Not yet determined

The appraisal serves as a reference to reveal SC's payments habits and ability to pay.  It is based on the 3 weighed factors:  Trade payment experience (through current enquiry with SC's suppliers), our delinquent payment and our debt collection record concerning SC.

 

Trade payment experience: SC did not provide any name of trade/service suppliers and we have no other sources to conduct the enquiry at present.

 

Delinquent payment record:   None in our database.

 

Debt collection record: No overdue amount owed by SC was placed to us for collection within the last 6 years.

 

 

Rounded Rectangle: BANKING

 BACKGROUND
 

 

 


At local AIC, the bank information of SC is not available.

 

 

Rounded Rectangle: FINANCIAL HIGHLIGHTS

 BACKGROUND
 

 

 


SC’s financial reports were not found during our checks with the local Administration for Industry and Commerce.

 

SC’s management declined to release any financial information.

 


Rounded Rectangle: REMARKS

 BACKGROUND

 

 


SC is considered medium-sized in its line with favorable background.


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.55.52

UK Pound

1

Rs.88.49

Euro

1

Rs.70.20

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.